Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.92
-0.37 (-3.28%)
At close: Oct 13, 2026, 4:00 PM EDT
11.13
+0.21 (1.92%)
After-hours: Oct 13, 2026, 7:30 PM EDT
Telix Pharmaceuticals Employees
As of December 31, 2025, Telix Pharmaceuticals had 1,184 total employees, including 1,120 full-time and 64 part-time employees. The number of employees increased by 950 or 405.98% compared to the previous year.
Employees
1,184
Change
950
Growth
405.98%
Revenue / Employee
$752,352
Profits / Employee
$28,291
Market Cap
3.74B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,184 | - | - | 1,120 | 64 |
| Mar 31, 2024 | 431 | 197 | 84.19% | 415 | 16 |
| Dec 31, 2022 | 234 | 76 | 48.10% | 234 | 0 |
| Dec 31, 2021 | 158 | - | - | 158 | 0 |
| Dec 31, 2017 | 9 | - | - | 9 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Acadia Pharmaceuticals | 798 |
| AbCellera Biologics | 562 |
| Xenon Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Relay Therapeutics | 202 |
| IDEAYA Biosciences | 145 |
| Parabilis Medicines | 145 |
TLX News
- 4 days ago - Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care - Nasdaq
- 4 days ago - Profound Medical enters co-education agreement with Telix Pharmaceuticals - TheFly
- 4 days ago - Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care - GlobeNewsWire
- 7 days ago - First U.S. Patient Receives Telix's Newly Approved Brain Cancer Imaging Drug - Nasdaq
- 7 days ago - Telix Pharmaceuticals’ brain cancer imaging drug applied on first U.S. patients - TheFly
- 7 days ago - First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18) - GlobeNewsWire
- 12 days ago - Ion Beam Enters Distribution Agreement For ARTMS' QIS Technology - Nasdaq
- 12 days ago - IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS® - GlobeNewsWire